Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY)

Name: Mouse Anti-C5b-9 Recombinant Antibody (aE11)
SKU: CBMAB-AO138LY
Rating: 5 (1 reviews)

See all C5b-9 antibodies

Compare Online Inquiry

Published Data

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in FC

(a, b) show C3 and C5b-9 binding, respectively, as determined by flow cytometry on whole bacteria. Both are statistically significant increased by the addition of FD to the deficient serum before vaccination, but this effect was lost postvaccination. The addition of anti-C1q resulted in complete inhibition of C3 deposition and strong reduction of C5b-9 deposition in all circumstances. ...View More

de Boer, E. C., Thielen, A. J., Langereis, J. D., Kamp, A., Brouwer, M. C., Oskam, N., ... & Jongerius, I. (2023). The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation. Clinical & translational immunology, 12(1), e1436.

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in ELISA

Regulation of AP activation. AP in normal human serum was activated in LPS coated wells. The inhibition achieved by addition of regulators was evaluated indirectly by quantifying C5b-9 complex formation by an ELISA-based method. AP activity was set to 100% for wells without regulators and wells with heat-inactivated serum were used as blank. Spontaneous activation was 42 ± 2.8%, measured in wells without LPS. Data represent mean values ± SD from 4 independent measurements. MFHR13 regulatory activity was significantly better than hFH (P < 0.0001, F(DFn, DFd) = 268.5 (1, 34)), and eculizumab (P < 0.0001, F(DFn, DFd) = 83.38 (1, 25)). ...View More

Ruiz-Molina, N., Parsons, J., Müller, M., Hoernstein, S. N., Bohlender, L. L., Pumple, S., ... & Decker, E. L. (2022). A synthetic protein as efficient multitarget regulator against complement over-activation. Communications Biology, 5(1), 152.

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in FC

Membrane attack complex formation using monoclonal mouse α-human C5b-9. Immune serum was used as a positive control for parasite lysis due to classical pathway activation. Flow cytometry data are shown as mean ± SEM from three independently performed experiments. Statistically significant differences between parasites incubated in immune vs. non-immune serum were determined using multiple Student's t test with Holm-Sidak correction for multiple comparisons, *p < 0.05, **p < 0.01, ***p < 0.001. ...View More

Sikorski, P. M., Commodaro, A. G., & Grigg, M. E. (2020). Toxoplasma gondii recruits factor H and C4b-binding protein to mediate resistance to serum killing and promote parasite persistence in vivo. Frontiers in Immunology, 10, 3105.

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in ELISA

C5b-9 formation was determined by ELISA after 30, 45, 60 and 75 min (n = 3). ...View More

Langereis, J. D., van der Molen, R. G., de Kat Angelino, C., Henriet, S. S., de Jonge, M. I., Joosten, I., ... & van der Flier, M. (2021). Complement factor D haplodeficiency is associated with a reduced complement activation speed and diminished bacterial killing. Clinical & Translational Immunology, 10(4), e1256.

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in FC

SARS-CoV-2 spike proteins induce C5b-9 deposition on the cell surface mainly through the alternative pathway. Flow cytometry demonstrated C5b-9 deposition on TF1PIGAnull cells after adding NHS preincubated with SARS-CoV-2 S1, S2, N, and HCoV-OC43 S proteins (2.5 µg/mL to 20 µg/mL) in either all pathway buffer (GVB++ pH 7.4) or APC-specific buffer (GVB0 10 mM MgEGTA pH 6.4). (A) SARS-CoV-2 S1, S2, and HCoV-OC43 S proteins elevated C5b-9 deposition in a dose-dependent manner in GVB++ buffer, whereas N protein did not increase C5b-9 from the baseline NHS level. (B) Both SARS-CoV-2 S1 and S2 led to marked increase of C5b-9 depositions in APC-specific buffer. By contrast, SARS-CoV-2 N and HCoV-OC43 S proteins showed minimal C5b-9 increase in APC-specific buffer. All experiments were repeated 6 times. Statistical significance was calculated between each 20 µg/mL CoV protein-treated group and the NHS-treated group (*P < .05, **P < .01, ***P < .001, ****P < .0001). ...View More

Yu, J., Yuan, X., Chen, H., Chaturvedi, S., Braunstein, E. M., & Brodsky, R. A. (2020). Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood, The Journal of the American Society of Hematology, 136(18), 2080-2089.

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in FC

A representative flow cytometry analysis demonstrated that 1 µM factor D inhibitor (dark blue curve) completely blocked the C5b-9 (left panel) and C3c deposition (right panel) triggered by 20 µg/mL S1 proteins (red curve). C5 inhibition with 50 µg of anti-C5 antibody (cyan curve) prevented S1-induced C5b-9 deposition, but not C3c accumulation. All experiments were repeated 3 times. Unpaired Student t test P values indicate statistical significance (*P < .05, **P < .01). ...View More

Mouse Anti-C5b-9 Recombinant Antibody (aE11) (CBMAB-AO138LY) in IF

Immunofluorescence of activated complement proteins C3d and C5b-9 at day 6 from control and atorvastatin-treated mice. Representative of staining done on 4-5 mice per group. ...View More

Tradtrantip, L., Duan, T., Yeaman, M. R., & Verkman, A. S. (2019). CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. Journal of neuroinflammation, 16, 1-13.

Datasheet

SDS

Request for COA

Datasheet Target Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

aE11

Application

E, IF

Immunogen

C5b-9 of human origin.

Host Species

Mouse

Specificity

Human, Pig

Antibody Isotype

IgG2a

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
ELISA	1:100-1:1,000
IF(ICC)	1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, 0.1% gelatin

Preservative

0.09% sodium azide

Concentration

0.1 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

C5b/6/7/8/9

Alternative Names

Terminal complement complex; TCC; C5b; C6; C7; C8; C9; Complement component

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-C5b-9 Recombinant Antibody (aE11)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-C5B-9 Recombinant Antibody (CBFYA-0216) (CAT#: CBMAB-X0304-FY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry